HomeLIFE • NASDAQ
aTyr Pharma Inc
$2.00
Pre-market:
$2.02
(1.00%)+0.020
Closed: Mar 28, 8:06:54 AM GMT-4 · USD · NASDAQ · Disclaimer
StockUS listed security
Previous close
$1.92
Day range
$1.92 - $2.09
Year range
$1.08 - $2.70
Market cap
135.15M USD
Avg Volume
697.59K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
(USD)Dec 2023Y/Y change
Revenue
0.00-100.00%
Operating expense
3.20M-6.48%
Net income
-14.76M-96.25%
Net profit margin
Earnings per share
-0.253.85%
EBITDA
-15.78M-99.52%
Effective tax rate
Total assets
Total liabilities
(USD)Dec 2023Y/Y change
Cash and short-term investments
98.17M48.41%
Total assets
120.65M25.96%
Total liabilities
30.18M23.19%
Total equity
90.47M
Shares outstanding
67.75M
Price to book
1.34
Return on assets
-32.47%
Return on capital
-36.44%
Net change in cash
(USD)Dec 2023Y/Y change
Net income
-14.76M-96.25%
Cash from operations
-11.06M-6.68%
Cash from investing
17.82M791.35%
Cash from financing
6.03M557.30%
Net change in cash
12.79M271.63%
Free cash flow
-5.14M46.87%
About
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases. The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients. The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla. Wikipedia
Founded
Jan 1, 2005
Employees
58
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu